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A B S T R A C T
Severe oral problems, including oral mucositis (OM) and xerostomia, often occur after conditioning therapy for
hematopoietic stem cell transplantation (HSCT). Saliva plays a major role in protecting the oral mucosa and teeth.
Alterations in salivary ﬂow rate or salivary components resulting in decreased salivary defence mechanisms may
affect oral/mucosal health and may inﬂuence the severity of OM. A systematic review was conducted to assess the
current scientiﬁc knowledge on changes in salivary function and composition before and after HSCT. All English
or Dutch articles examining salivary ﬂow rate or salivary components before and after HSCT were included after
title/abstract selection by 2 independent reviewers (weighted k = .91). After quality assessment and exclusion of
all research groups with both children age <14 years and adults, 33 articles were included for data analysis. Over-
all, the salivary ﬂow rate was decreased at several days and months after HSCT. Although several salivary compo-
nents were studied, most components were examined in only 1 or 2 studies with different patient populations or
at different time points after HSCT. At 7 days after HSCT, albumin and proinﬂammatory cytokines were increased,
whereas secretory IgA and components of the salivary antioxidant system were decreased. Secretory IgA levels
were still reduced at 1 month after HSCT but returned to pre-HSCT values at 6 months after HSCT. Lactoferrin,
secretory leukocyte protease inhibitor, and b2-microglobulin levels were increased at 6 months after HSCT. Our
ﬁndings show that changes in saliva reﬂect an inﬂammatory response occurring immediately after HSCT, followed
by evidence of increased salivary antimicrobial defense mechanisms by 6 months after HSCT.
© 2019 American Society for Blood and Marrow Transplantation. This is an open access article under the CC BY-
NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is used in
the treatment of leukemia, lymphoma, and other severe blood
diseases and may be either autologous or allogeneic, depend-
ing on the stem cell graft source. Before HSCT, patients receive
conditioning therapy consisting of high-dose chemotherapy
and/or radiotherapy.
A common oral complication in the early days after HSCT as
a result of this conditioning therapy is oral mucositis (OM). OM
is characterized by erythema, swollen mucosa, and ulcerations.
In severe cases, it is extremely painful, which may affect the
patient's ability to eat, drink, and/or sleep. In such cases, the
use of opioids for pain relief is often required, and there is an
increased risk of severe systemic infections due to ulcerations
[1]. Despite recent advances in the development of reduced-
intensity conditioning therapy regimens, OM remains preva-
lent, with severe OM (score 2 to 4) seen in 50% to 70% of HSCT
recipients [2,3].
Another common complication after allogeneic HSCT is
chronic graft-versus-host disease (cGVHD), which occurs
within several months after HSCT in approximately 25% to 80%
of patients [4]. It can affect multiple organs, with commonly
affected sites including the skin, mouth, and liver [5]. Oral
cGVHD is characterized by lichenoid lesions, erythema, and
ulcerations, and subjective complaints include pain, taste
changes, and sensitivity. The salivary glands also may be
affected, resulting in hyposalivation and xerostomia [6,7].
Saliva, a mixture of mainly water, ions, and proteins, pro-
tects the teeth and oral mucosa through buffering capacity,
remineralization, and antimicrobial actions. Such proteins as
defensins, cystatins, lactoferrin, and the immunoglobulins are
important for this antimicrobial action [8]. Alterations in the
function and/or composition of saliva resulting in decreased
salivary defense mechanisms may affect oral/mucosal health
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[9,10]. This systematic review was performed to evaluate the
current scientiﬁc knowledge regarding changes in salivary
function and protein composition before and after HSCT.
METHODS
Search Strategy
A literature search extending up to August 2017 was conducted by an
investigator in consultation with a medical librarian in the electronic data-
bases Embase, MEDLINE, and Web of Science. Search terms (including MeSH
[Medical Subject Headings] terms, Emtree terms, and free text terms) related
to hematopoietic stem cell transplantation and saliva were used for a search
in title, abstract, and authors’ keywords. The search terms were identiﬁed
using index terms of previously identiﬁed key articles (Table 1).
Selection Criteria
All articles written in English or Dutch were selected from the electronic
search based on title and abstract by 2 independent investigators. All articles
assessing salivary function and/or components (eg, ﬂow rate, proteins, cyto-
kines) in patients undergoing HSCT or bone marrow transplantation were
selected, and full text was obtained for quality assessment. For the selection
on title and abstract, articles were scored with “no,” “?,” or “yes.” In case of
one “?” or disagreement, a consensus was reached. A third investigator could
be consulted in the event of disagreement.
Quality Assessment and Data Extraction
Quality assessment was performed using a checklist based on the STROBE
checklist with the explanatory article [11,12]. Eighteen items from this check-
list (method, results and discussion section) were used for the quality assess-
ment. If an item was not properly recorded, this was considered a potential
source of bias. All items described properly were scored with a “+,” corre-
sponding to 1 point. All articles with 10 points were included for data
extraction and data analysis.
Data Extraction and Analysis
Data extraction was performed by an investigator using an extraction
form and included the number of patients, age range of the study population,
type of conditioning therapy/stem cell transplantation, saliva collection
method, salivary analysis method, time points of collection (day 0 is day of
HSCT), and data on ﬂow rate and salivary components. All studies with chil-
dren in the study population were checked separately for age range of the
participants. Studies with only children or studies with children age
14 years were included in the analysis. All other studies with children and
adults that did not separately report the results in the 2 groups were
excluded from data analysis due to the differences in salivary composition
between children and adults (11 articles) [13].
The Psy package, version 1.1 was used with R version 3.4.1 (R Institute for
Statistical Computing, Vienna, Austria) to calculate the squared weighted k
value for the agreement between the 2 investigators in the selection of
articles.
RESULTS
Selection of Articles
The search yielded a total of 780 articles (with publication
dates ranging from 1964 to 2017), of which 570 articles
remained after removal of duplicates and language selection
(Figure 1). Selection on title and abstract by 2 independent
investigators resulted in 75 articles for full text and quality
assessment (weighted k = .91). Studies with low-quality or no
follow-up after HSCT or control group were excluded. Finally, a
total of 33 articles were included for data analysis.
The time points of assessment after HSCT varied among the
articles. Some studies performed assessment in the early days
after HSCT and other studies performed assessments several
months after HSCT. No studies including an adult study popu-
lation combined both short-term and long-term assessments.
Flow Rate
A total of 12 articles measured salivary ﬂow rate in adult
HSCT recipients in relation to time after HSCT, GVHD, OM, and/
or conditioning therapy (Supplementary Table S1). Another 10
articles measured salivary ﬂow rate in children or children age
14 years and adults (Supplementary Table S2). Overall, a
trend toward decreased salivary ﬂow rates was seen several
days to months after HSCT compared with pre-HSCT levels in
autologous and allogeneic HSCT recipients (Figure 2; Supple-
mentary Tables S1 and S2) [1417]. In the early days after
HSCT, 1 study found an increase at days +8/+10 in allogeneic
HSCT recipients [18], while no differences in salivary ﬂow rates
were seen in autologous and allogeneic HSCT recipients
[19,20]. Overall, salivary ﬂow rates appeared to improve over
time; however, the studies are conﬂicting with respect to the
time span. Improvement of salivary ﬂow rate was reported at
2 and 12 months after autologous and allogeneic HSCT [17,21],
whereas a decrease at around 3 months after allogeneic HSCT
was found in another study [18] (Figure 2).
Along with the trend toward decreasing salivary ﬂow rate,
hyposalivation and xerostomia are frequently seen in autolo-
gous and allogeneic HSCT recipients. Compared with healthy
controls, hyposalivation was more prevalent in adult autolo-
gous and allogeneic HSCT recipients before HSCT and at 6 and
12 months after HSCT [21]. Two other studies including chil-
dren age 14 years and adults also found high prevalences of
hyposalivation and xerostomia up to 12 months [22] and
1095 days [23] after HSCT. Several years after HSCT, hyposali-
vation and xerostomia were still prevalent in children [24].
Salivary dysfunction was seen in unstimulated and stimu-
lated glandular saliva of adult HSCT recipients with aGVHD
compared with age- and sex-matched individuals and HSCT
recipients without GVHD [25]. Conﬂicting results for salivary
ﬂow rate were found in patients with oral cGVHD. A decreased
unstimulated whole salivary (UWS) ﬂow rate was found in
patients with aGVHD [17] and those with oral cGVHD (with
mucosal lesions, xerostomia, and restricted mouth opening as
symptoms) [26,29], whereas no difference in UWS ﬂow rate
was reported in 2 studies in which only mucosal lesions were
Table 1
Search Terms used in the Literature Search
MeSH terms Emtree Terms Text Terms
Cord blood stem cell transplantation Hematopoi-
etic stem cell transplantation
(Allogeneic/autologous) hematopoietic stem cell transplantation Hematopoietic stem cell transplantation
Peripheral blood stem cell transplantation (Allogeneic/autologous/cord blood/peripheral blood/ nonmyeloa-
blative) stem cell transplantation
HSCT
Bone marrow/transplantation (Allogeneic/autologous) bone marrow transplantation ASCT
Saliva Saliva/saliva analysis/ hyposalivation Saliva
Salivary proteins and peptides/histatins/mucin-
5b/ salivary amylases/salivary cystatins/salivary
proline-rich-proteins
Saliva protein/proline-rich protein/alpha amylase saliva
isoenzyme
Salivary proteins/mucin/ histatin/salivary
alpha amylase/cystatin/proline-rich
proteins
Salivary glands/parotid gland/salivary ducts/sali-
vary glands, minor/sublingual gland/submandib-
ular gland/von Ebner glands
Salivary gland function/ salivation disorder/salivary gland/minor
salivary gland/ parotid salivary gland/salivary gland duct/sublin-
gual gland/ submandibular gland/von Ebner gland
Parotid gland/sublingual gland/subman-
dibular gland
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included as oral cGVHD symptoms [27,28] (Supplementary
Table S1).
Only 2 of 4 included articles studying OM and salivary ﬂow
rate calculated a correlation or determined differences in
patients with OM and those without OM. No correlation or dif-
ferences in salivary ﬂow rate were found between patients
with OM and those without OM [14,15].
The studies including only children in the study population
compared salivary ﬂow rate in groups that received different
conditioning regimens (Supplementary Table S2). The use of
total body irradiation (TBI) in the conditioning regimen
resulted in decreased salivary ﬂow rates several years after
HSCT compared with the use of only chemotherapy as condi-
tioning therapy [3032]. The administration of TBI over sev-
eral days (ie, fractionated TBI) resulted in higher salivary ﬂow
rates at 1 year after HSCT [33] compared with single-session
TBI; however, in 1 study in patients at the age of 15 and at 2 to
14.5 years after HSCT, no differences were found between the
2 TBI administration regimens [34]. A study including patients
age 16 years found decreased salivary ﬂow rates in UWS and
Figure 1. Flow diagram of the article selection process.
Figure 2. Changes in salivary ﬂow rate after HSCT compared with before HSCT in adult HSCT recipients. ", increase; #, decrease; , no change. The black horizontal
line represents the time span of the study, and the small black vertical lines represent the time points of saliva collection. The black dashed line indicates that the
study period was different for some patients in the study. Further details of the studies are provided in Supplementary Table S1.
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stimulated whole saliva (SWS) in allogeneic and autologous
HSCT recipients at 4 to 14 weeks after TBI in the longitudinal
group, but no differences in salivary ﬂow rates at 8 months to
7 years after TBI in the retrospective group [35].
Saliva Composition
Various salivary components have been studied after HSCT;
however, most components were evaluated in only 1 or 2 stud-
ies with different study populations and/or time spans
(Figure 3; Supplementary Table S3). The most studied type of
saliva in the included studies was whole mouth saliva; only 2
studies evaluated glandular saliva (Supplementary Table S3).
Although there was no change in UWS total protein con-
centration in autologous HSCT recipients, several proteins
were increased in UWS and stimulated submandibular (SM)/
sublingual (SL) saliva several days and months after autologous
and allogeneic HSCT [10,17,19]. Increased albumin levels were
found at day +7 in autologous HSCT recipients and at 1 month
post-transplantation in allogeneic HSCT recipients [10,19]. In
stimulated SM/SL saliva, increased levels of lactoferrin, secre-
tory leukocyte protease inhibitor (SLPI), and b2-microglobulin
were seen 6 months after allogeneic HSCT [10] (Figure 3; Sup-
plementary Table S3). At several days after autologous HSCT,
several components of the salivary antioxidant system were
decreased in UWS, leading to decreased salivary antioxidative
capacities [17,19,36]. In addition, a decrease in secretory IgA
was found at day +7 in UWS of adult autologous HSCT recipi-
ents and at 1 month after allogeneic HSCT in stimulated SM/SL
saliva of adult patients [10,19] (Figure 3; Supplementary Table
S3). In SWS, decreased levels of secretory IgA and IgG were
found at 1, 2, and 3 months after autologous and allogeneic
HSCT in children age 14 years and adults [37].
Overall, a trend toward increasing levels of proinﬂamma-
tory cytokines, such as as TNF-a and IL-1, in the ﬁrst days after
autologous and allogeneic HSCT, although some contradictory
results in salivary TNF-a levels in UWS and SWS have been
reported [15,38,39] (Figure 3; Supplementary Table S3). Little
is known about changes in the anti-inﬂammatory cytokines;
only 1 study found increased levels of IL-10 in UWS and SWS
of adult allogeneic HSCT recipients at days +7 and +14 [15].
Only limited research has been reported on other salivary
components, such as matrix metalloproteinases, epidermal
growth factors, and salivary prostaglandins (Supplementary
Tables S3 and S4) [15,20,40].
In the study groups that included both children  14 years
of age and adults, the salivary components were only studied
once (Supplementary Table S4). Similar to the studies with
only adults, an increasing trend was observed in UWS TNF-a,
however a decreasing trend was observed for UWS IL-1b sev-
eral days after autologous and allogeneic HSCT [20]. Increasing
trends were also observed for the cytokines IL-6, CXCL8/IL-8
and IL-10 the metalloproteinase MMP2/TIMP-2 and the growth
factors FGF, EGF and VEGF levels in UWS several days after
autologous and allogeneic HSCT [20,41]. Decreasing trends
were observed for myeloperoxidase (MPO) and the matrix
metalloproteinase MMP9/TIMP-2 [20,41]. In aGVHD patients
(children  14 years of age and adults) similar trends for total
protein (no change) and uric acid (decreasing trend) were
observed compared to the studies including only adult HSCT
recipients [17].
In patients with cGVHD, increased levels of total protein,
albumin, IgG, IL-1a, and IL-6 were found compared with healthy
controls and age- and sex-matched allogeneic HSCT recipients
without cGVHD [29,42,43] (Supplementary Table S3). Apart
from targeted assays, a proteomics approach was also reported
for the discovery of biomarkers for cGVHD. Differently
expressed proteins in UWS of adults with mucosal GVHD com-
pared with patients without GVHD or healthy controls included
IL-1 receptor antagonist, cystatin-B, lactoperoxidase, and lacto-
transferrin (Table 2) [27,28]. Mucin 16 and colony-stimulating
factor 2 receptor b were also differentially expressed between
adults with cGVHD (oral symptoms not speciﬁed) and healthy
controls (Table 2) [44]. Moreover, 3 proteins S100A7, S100A8,
and S100A9 short were differentially expressed between alloge-
neic patients with GVHD and those without GVHD and healthy
individuals in a study including children age 14 years [45].
In addition to the compositional changes in proteins,
changes in the inorganic components have been reported
[18,19]; however, these changes were beyond the scope of this
systematic review.
DISCUSSION
This systematic review was performed to assess the current
scientiﬁc knowledge on changes in salivary function and com-
position before and after HSCT. Overall, salivary ﬂow rate was
decreased at several days and months after HSCT. In the ﬁrst
week after HSCT, levels of albumin and proinﬂammatory cyto-
kines were increased, whereas levels of secretory IgA and com-
ponents of the salivary antioxidant system were decreased.
Increased levels of lactoferrin, SLPI, and b2-microglobulin were
found at 6 months after HSCT.
Although salivary ﬂow rate appeared to show an overall
trend toward reduction after HSCT, most studies assessing sali-
vary ﬂow rate in the ﬁrst days after HSCT showed only a slight
change in salivary ﬂow rate. One explanation for this small
change might be related to the type of conditioning therapy. In
those studies, the conditioning therapy mostly involved che-
motherapy; only some patients were treated with TBI in com-
bination with chemotherapy in 2 studies [14,18]. As shown in
a systematic review assessing salivary gland dysfunction and
xerostomia in different cancer therapies, salivary gland dys-
function is less severe after chemotherapy than after radiation
therapy [46]. A possible explanation for the signiﬁcant increase
in salivary ﬂow rate found in the second week after HSCT in 1
study might be dysphagia caused by the conditioning therapy,
as discussed by the authors [18].
A decreased salivary ﬂow rate negatively affects the protec-
tive function of saliva and may result in oral complications.
This probably explains the association observed between sali-
vary hypofunction and oral mucositis [9]. Low salivary ﬂow
rates at baseline and during chemotherapy were identiﬁed as
risk factors for OM in a study including 63 cancer patients
receiving 5-ﬂuorouracil as chemotherapy [47]. Furthermore, in
the treatment groups of the intervention study included in this
review, receiving a sialogogue therapy to stimulate salivary
ﬂow rate, less severe oral mucositis was found compared with
that the control group [15]. In the ﬁrst 2 weeks after HSCT, a
trend toward decreasing salivary ﬂow rate was also found in
these treatment groups, but the decrease was less than that
seen in the control group [15]. Moreover, higher values of sali-
vary ﬂow rate were found in the surviving patients in this
intervention study [15].
Changes in the salivary composition after HSCT were also
found. In the ﬁrst 2 weeks after HSCT, a decreased salivary
antioxidant capacity was reported [19,36]. The chemothera-
peutic agents induce epithelial cell damage and consequently
induce the generation of reactive oxygen species (ROS) [48].
One of the protective components in saliva is superoxide dis-
mutase (SOD), which inhibits the production of free radicals
[36]. In the ﬁrst 2 weeks after HSCT, salivary SOD levels were
1058 S.J.M. van Leeuwen et al. / Biol Blood Marrow Transplant 25 (2019) 10551061
Figure 3. Compositional changes in saliva after HSCT compared with before HSCT in adult HSCT recipients. ", increase; #, decrease;, no change. The black horizontal
line represents the time span of the study, and the small black vertical lines represent the time points of saliva collection. The black dashed lines indicate that the
study periods were different for some patients in that study. Changes in saliva represent changes in all types of saliva; saliva types are characterized in Supplementary
Table S3.
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signiﬁcantly increased in 1 study [19] and only marginally (not
signiﬁcantly) increased in another study [36], indicating com-
pensation for the increased generation of ROS [19,36]. How-
ever, the compensation is not complete, as can be deduced
from a decrease in total antioxidant capacity [19]. This
decreased salivary antioxidant capacity might facilitate muco-
sal damage, as has been suggested in elderly patients, in whom
it might be a risk factor for oral cancer [49].
Another factor that may promote oral mucosal damage is
diminishing defense mechanisms, such as decreased levels of
secretory IgA in the ﬁrst 2 weeks after HSCT [19]. Oral mucosal
damage is accompanied by increased levels of albumin, possi-
bly due to increased permeability of the damaged mucosae
reported within the ﬁrst 2 weeks [19] and within 1 month after
HSCT [10]. In mice lacking the secretory component of IgA,
increased levels of the serum-born components albumin and
IgG were found in whole saliva, also indicating increased
mucosal permeability [50]. Although the knockout mice in that
study lacked secretory IgA, their IgA levels, derived from serum
and consisting only of the monomeric form instead of the
dimeric secretory form of IgA normally found in saliva, were
similar to those measured in wild-type mice [50].
Oral mucosal damage is not only seen in the ﬁrst 2 weeks
after HSCT, but also may occur several months after HSCT in
allogeneic HSCT recipients with oral cGVHD. In patients with
cGVHD, indications of increased membrane permeability were
demonstrated by increased levels of albumin, total protein,
and IgG [29]. A possible explanation for the oral mucosal dam-
age in those patients might be decreased salivary antioxidant
capacity, as described by Nagler et al [17].
In cGVHD, 3 different oral manifestations have been
hypothesized to occur: mucosal cGVHD, restricted mouth
opening, and salivary gland involvement [51]. In cases of sali-
vary gland dysfunction, lymphocytic inﬁltrates are found in
the salivary glands, leading to hyposalivation and composi-
tional changes. The hypothesis of the 3 different oral manifes-
tations of oral cGVHD may explain the conﬂicting salivary ﬂow
rate data in cGVHD patients in this review [18,2529]. The
compositional changes may be similar to those found in the
saliva of patients with Sj€ogren's syndrome [10]. The increased
levels of lactoferrin, b2-microglobulin, and SLPI found in stimu-
lated SM/SL saliva at 6 months after allogeneic HSCT may
reﬂect salivary inﬁltrates [10].
Compositional changes in the saliva occurring in different
forms of oral cGVHD are unknown. For the differences in total
protein, albumin, IgA, and IgG reported in patients with
cGVHD, the type of cGVHD was not speciﬁed. However, 2 stud-
ies that included patients with cGVHD with oral mucosal
changes identiﬁed cystatin-B, IL-1 receptor antagonist protein,
lactotransferrin, and lactoperoxidase as differently expressed
proteins in patients with mucosal cGVHD compared with
cGVHDwithout oral involvement and healthy adults. For a bet-
ter understanding of the compositional changes in saliva in
cGVHD patients, separation of the different types of cGVHD is
important, especially when studying compositional changes in
saliva in cGVHD patients with salivary gland involvement.
Moreover, prospective observational studies that include both
short-term and long-term measurements in HSCT recipients
are required.
In conclusion, overall the evaluated studies showed a trend
toward decreasing salivary ﬂow rate at both several days and
several months after HSCT and reported compositional
changes in saliva reﬂecting an inﬂammatory response directly
after HSCT, followed by increases in salivary antimicrobial
defense mechanisms at 6 months after HSCT. However, these
conclusions are based on studies in differing study populations
and different types of saliva collected at different follow-up
times after HSCT. No single study included both short-term
and long-term follow-up.
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